
Opinion|Videos|December 8, 2023
Navigating Endocrine Resistance in the Treatment of ER+/HER2- Metastatic Breast Cancer
Author(s)Hope S. Rugo, MD
Current treatment landscape in ER+/HER2- metastatic breast cancer and unmet needs in overcoming treatment resistance.
Advertisement
Episodes in this series

Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
2
The Targeted Pulse: New Standards in Myeloma, Melanoma, and More
3
Onvansertib Triplet Shows Dose-Dependent Frontline Benefit in RAS-Mutant Metastatic CRC
4
Pembrolizumab/Lenvatinib Show Efficacy, Safety in Clear Cell Gyn Cancers
5




















